Skip to content
跳至主要內容
SPY
···
QQQ
···
IWM
···
DIA
···
AAPL
···
MSFT
···
NVDA
···
GOOGL
···
AMZN
···
META
···
TSLA
···
BRK.B
···
JPM
···
GLD
···
TLT
···
BTC
···
ETH
···
VIXY
···
UUP
···
USO
···
SPY
···
QQQ
···
IWM
···
DIA
···
AAPL
···
MSFT
···
NVDA
···
GOOGL
···
AMZN
···
META
···
TSLA
···
BRK.B
···
JPM
···
GLD
···
TLT
···
BTC
···
ETH
···
VIXY
···
UUP
···
USO
···
Stock detail
Loading institutional stock data...
← BACK TO COCKPIT
ALL TICKERS →
OPTIONS CHAIN →
ALT
Altimmune, Inc.
NASDAQGM
Biotechnology
United States
$3.42
▲
+0.19 (+5.88%)
CLOSED
—
OPEN
$3.28
HIGH
$3.43
LOW
$3.25
PREV CLOSE
$3.23
VOLUME
4.85M
1.09x avg
BID / ASK
2.24 / 3.92
spr 1.680
MARKET CAP
$665.3M
DAY RANGE
$3.25
$3.43
P/E (TTM)
—
Fwd -5.1
EPS (TTM)
-0.76
DIV YIELD
—
ex-div 2017-01-20
52W HIGH
$6.44
-46.9%
52W LOW
$2.56
+33.6%
BETA
0.18
vs S&P 500
DES
FA
GP
OPT
HLDR
EARN
CMP
COMPARE
ASK DESK
AFTER-HOURS
$3.44
+0.02
(+0.58%)
LAST SURPRISE
—
—
NEXT EARNINGS
—
—
CATALYST
No fresh catalyst
—
ANALYST
—
—
SHORT INT
—
—
OPTIONS IV
—
—
ALT
$3.42
▲
+5.88%
Chart
Valuation
Financials
Peers
News
ALT · K 線技術分析（即時、可互動）
basic
pro
快速分析（約 90–120 秒）
K 線圖載入中…
按上方「快速分析」，研究台會以這張 K 線為起點跑一輪快速回答：三個分析師視角（總經、基本面、技術面）加交易計畫與風險統計，約 90–120 秒。想要五隊深度研究與機構級報告，請在研究台把模式切到「深度」。
1-YEAR PRICE
One-Year Trajectory
MIXED
252 BARS · -9.5% YOY
1-year price chart. Started at 3.78, currently 3.42, down 9.5 percent. Range 2.59 to 6.18 over 252 data points.
2025-09-05
$3.78 → $3.42 (-9.5%)
2026-09-04
§ Valuation
Loading § Valuation
§ Multi-Year Financials
Loading § Multi-Year Financials
§ Peers
Loading § Peers
§ Recent News
Loading § Recent News
EDITORIAL · NOT INVESTMENT ADVICE.
Data sources: Finnhub (quote / profile / news / peers) + Yahoo (stats) + SEC EDGAR XBRL (financials + DCF). All values cached for 5 minutes via ISR.
VALUATION
Deterministic Valuation (SEC EDGAR + Finnhub)
—
NO DCF
DCF Fair Value
—
DCF vs Spot
—
Comps Fair Value
$6.53
WACC Used
+7.0%
Terminal g
+3.5%
Verdict: hold
· peers $6.53 (+90.9%)
Peers:
AS PE31
APTV PE21
ATI PE62
BCE PE5
BMRN PE180
BRKR
CPT PE35
CVNA PE39
⚠ DCF skipped: missing FCF or shares data from SEC EDGAR. Often the case for non-US issuers.
FINANCIALS
Multi-Year Financials (SEC XBRL)
—
4 FY · NO YOY
FY
Revenue
Net Income
OCF
FCF
Assets
2025-12
—
-$88.1M
-$67.5M
-$67.5M
$279.9M
2024-12
—
-$95.1M
-$79.8M
—
$139.3M
2023-12
—
-$88.4M
-$75.8M
-$75.9M
$210.6M
2021-12
$4.4M
—
—
—
—
PEERS
Sector & Industry Peers
CALM
10 PEERS · FINNHUB
AS
APTV
ATI
BCE
BMRN
BRKR
CPT
CVNA
CRBG
EQH
NEWS
Recent News (past 14 days)
CALM
10 HEADLINES · LAST 14 DAYS
Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference
GlobeNewswire · 2026-09-03
Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger?
Zacks · 2026-08-19
Altimmune's Phase III MASH Study Puts 2029 Data in Investor Focus
Zacks · 2026-08-19
Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in Focus
Zacks · 2026-08-14
ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus
Zacks · 2026-08-13
Altimmune Inc (ALT) (Q2 2026) Earnings Call Highlights: Advancing MASH and AUD Pipelines with ...
GuruFocus.com · 2026-08-12
Altimmune Q2 Earnings Call Highlights
MarketBeat · 2026-08-12
BLTE Stock Rises as FDA Grants Priority Review to Tinlarebant NDA
Zacks · 2026-08-12